Background
==========

There are nearly 60 million individuals infected with Human Immunodeficiency Virus (HIV) since the early 1980s, and at least 25 million HIV-infected individuals have died of Acquired Immunodeficiency Syndrome (AIDS) since the beginning of the epidemic \[[@B1]\]. AIDS has decreased life expectancies by 20 years, and the high rates of HIV infection in adolescents and women of reproductive age have resulted in community destruction, family dissolution, and economic loss in many sub-Saharan African countries. AIDS prevention program has been actively performed, and there has been significant ongoing research focused on the development of an HIV vaccine and effective antiretroviral drugs. As a result, the dead by AIDS has decreased from 2.2 million in 2005 to 2 million in 2007 and newly HIV-infected individuals have also reduced recently \[[@B1]\]. AIDS-associated mortality increased by 16% year by year to the mid-1990s and then was raised as first cause of adult death, however, it has rapidly decreased since the mid-1990s in the United States \[[@B2]\]. This decrease in AIDS-associated mortality coincided with the introduction of highly active antiretroviral therapy (HAART), including protease inhibitors \[[@B3]\], suggesting that survival following HIV infection increased from 10--12 years to 25 years \[[@B4],[@B5]\].

A total of 5,323 individuals have been diagnosed with HIV infection between 1985 and 2007 in Korea. Approximately 91% of infected individuals were male and 99% were infected by sexual contact \[[@B6]\]. HIV-infected individuals may refuse antiretroviral therapy because of efficacy concerns and social stigmas. Additionally, patients and their families may remain unconvinced by positive antiretroviral effects on survival times \[[@B7]\]. There are no current estimates describing the survival of HIV-infected individuals in Korea, and we therefore assumed that HIV survival times might have increased with the advent of governmental support for therapy and the introduction of HAART in 1997. The number of newly diagnosed HIV-infected individuals in Korea and the target population for therapy is increasing, and it is therefore necessary to assess the national HIV/AIDS prevention program of therapy for HIV-infected individuals. It is therefore necessary to estimate HIV/AIDS survival in Korea in order to predict governmental budgets for therapy.

It is difficult to predict the time of HIV infection in this population since the majority of reported HIV infections in Korea are the result of sexual contact. This study investigated survival times, survival characteristics, and the changes in survival times following HIV diagnosis. This study also evaluated the immune status of individuals at HIV diagnosis to elucidate the association between survival and CD4+ T-cell counts at primary HIV diagnosis.

Methods
=======

HIV diagnosis and the National control of HIV/AIDS
--------------------------------------------------

HIV-reactive samples from screening testing centers were referred to local Institutions of Health and the Environment (IHEs) or the Division of AIDS at the Korea Centers for Disease Control and Prevention (KCDC) to confirm HIV infection. Results of HIV infection were transferred to the Division of HIV & TB Control at the KCDC. Individuals were automatically registered as infected unless they were anonymously tested. Epidemiological investigations, public health education programs, connection to medical center, and therapy costs were supported by Public Health Centers (PHCs). HIV-associated deaths were documented by PHCs, and medical certificates with the dates, places, and reasons of death were reported to the Division of HIV & TB Control in KCDC. Additionally, immune testing of registered individuals was performed on a regular basis by the Division of AIDS at the KCDC or by medical centers \[[@B6]\].

Subjects
--------

A total of 5,323 HIV-infected individuals were registered at the KCDC from 1985 to 2007 in Korea. Data from these individuals were investigated to estimate survival and their association with epidemiologic characteristics following HIV diagnosis. Survival according to immune status at HIV diagnosis were estimated in individuals with initial CD4+ T-cell counts at HIV diagnosis (n = 3,369). They were older than 14 years of age at HIV diagnosis and had available initial CD4+ T-cell counts within 6 months of HIV diagnosis including individuals died of AIDS within 6 months after HIV diagnosis.

Selection criteria
------------------

The date of HIV diagnosis was defined as the date when the KCDC or local IHEs confirmed a sample as HIV-positive. Survivals were analyzed with epidemiological variables including gender, age, screening site, year of diagnosis, and immune status at HIV diagnosis. Screening sites were classified into three groups: public institutions, hospitals, and blood centers \[[@B8]\]. Year of diagnosis were grouped by changes in drug introduction and therapeutic administration. Zidovudine (AZT) monotherapy was introduced to the Korean HIV therapeutic system in 1991 \[[@B9]\], and HAART was introduced in 1997 \[[@B10]\]. HIV RNA quantitative assays have been performed at the Division of AIDS at the KCDC or in medical centers to monitor the efficacy of therapy since late 2002. Categories included: no antiretroviral therapy (1985--1990), AZT monotherapy (1991--1996), HAART (1997--2002), and use of HIV RNA quantitative tests for monitoring (2003--2007). The immune status of infected individuals was stratified into four categories by CD4+ T-cell counts (\<200 cells/mm^3^, 200--349 cells/mm^3^, 350--499 cells/mm^3^, and ≥500 cells/mm^3^) based on the 1993 revised classification system for HIV infection \[[@B11]\] and the 2002 guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents by Centers for Disease Control and Prevention of United States \[[@B12]\].

Statistical analysis
--------------------

Follow-up of HIV-infected individuals for survival analysis of 5,323 individual was performed until December 32, 2007. Kaplan-Meier analysis and log-rank tests were used to compare survival curves stratified by epidemiological group. The Cox\'s proportional hazards model was applied to examine the association between variables and survival times. We classified 1,954 individuals without CD4+ T-cell counts or CD4+ T-cell counts taken greater than 6 months after HIV diagnosis into the \"missing group\" in the multivariate analysis to adjust the confounding. The results of the missing group were not shown in Table [1](#T1){ref-type="table"}. Analysis was performed using the SAS version 9.1 software packages, and the STATISTICA program was used for survival graph.

###### 

Characteristics of the study population, 1985--2007

  --------------------------------------------------------------------------------------------------------------------------
  Categories            All (%)      No. of deaths\   No. of deaths within\        Person-years   Mortality density\
                                     (%)              6 months of diagnosis(%)\*                  (per 1,000 person-years)
  --------------------- ------------ ---------------- ---------------------------- -------------- --------------------------
  Total individuals     5,323        980 (18)         441 (45)                     21,439         45.7

  Gender                                                                                          

   Men                  4,861 (91)   901 (19)         413 (46)                     19,082         47.2

   Women                462 (9)      79 (17)          29 (37)                      2,357          33.5

  Age                                                                                             

   ≤ 29                 1,363 (26)   148 (11)         25 (17)                      7,153          20.7

   30--39               1,758 (33)   283 (16)         102 (36)                     7,506          37.7

   40--49               1,220 (23)   268 (22)         136 (51)                     4,081          65.7

   ≥ 50                 982 (18)     281 (29)         179 (64)                     2,699          104.1

  Screening site                                                                                  

   Public institution   1,394 (26)   296 (21)         51 (14)                      8,031          36.8

   Hospital             3,448 (65)   644 (19)         390 (56)                     10,632         60.6

   Blood center         481 (9)      40 (8)           1 (9)                        2,776          14.4

  Year of diagnosis                                                                               

   1985--1990           124 (2)      86 (69)          5 (6)                        1,403          61.3

   1991--1996           497 (10)     215 (43)         35 (16)                      4,878          44.1

   1997--2002           1,388 (26)   339 (24)         146 (43)                     8,202          41.3

   2003--2007           3,314 (62)   340 (10)         256 (75)                     6,956          48.9
  --------------------------------------------------------------------------------------------------------------------------

\*%; proportion of the number of the deaths within 6 months after HIV diagnosis divided by the number of deaths

Results
=======

Epidemiological characteristics of study populations
----------------------------------------------------

The majority (91%) of HIV-infected individuals (n = 4,861) were men (Table [1](#T1){ref-type="table"}). The greatest proportion of HIV-infected individuals were aged 30--39 years (33%), and 65% of all infections were identified in hospitals. Additionally, 62% were diagnosed between 2003 and 2007 and 18% (n = 980) died before the end of the study. Additionally, 45% of individuals died within 6 months of HIV diagnosis, and many of these patients were aged 40 years and older, were initially detected in hospitals (56%), and were diagnosed between 2003 and 2007 (75%).

###### 

Proportion of survival following HIV diagnosis and the estimated hazard ratios for variables

                                               Unadjusted        Adjusted                     
  ---------------------- ------- ------------- ----------------- ---------- ----------------- ----------
  Gender                                                                                      
   Men                   4,861   67%(64--69)   1.31(1.04,1.65)   0.0211     1.37(0.09,1.73)   0.0082
   Women                 462     73%(66--78)   1.00              \-         1.00              \-
  Age                                                                                         
   ≤ 29                  1,363   81%(77--84)   1.00              \-         1.00              \-
   30--39                1,758   71%(66--74)   1.80(1.47,2.20)   \< .0001   1.46(1.19,1.80)   0.0003
   40--49                1,220   56%(50--63)   2.94(2.40,3.61)   \< .0001   2.10(1.70,2.60)   \< .0001
   ≥ 50                  982     49%(41--57)   4.37(3.56,5.35)   \< .0001   3.08(2.48,3.83)   \< .0001
  Screening site                                                                              
   Public institution    1,394   68%(64--71)   1.00              \-         1.00              \-
   Hospital              3,448   68%(64--72)   1.47(1.27,1.70)   \< .0001   1.50(1.27,1.76)   \< .0001
   Blood center          481     85%(78--89)   0.39(0.28,0.55)   \< .0001   0.62(0.44,0.88)   0.0067
  Year of diagnosis                                                                           
   1985--1990            124     56%(46--64)   2.15(1.65,2.80)   \< .0001   5.03(3.77,6.71)   \< .0001
   1991--1996            497     62%(57--66)   1.57(1.29,1.90)   \< .0001   3.48(2.81,4.30)   \< .0001
   1997--2002            1,338   70%(66--73)   1.31(1.11,1.54)   0.0011     1.42(1.21,1.68)   \< .0001
   2003--2007            3,314   \-            1.00              \-         1.00              \-
  CD4+ T-cell counts\*                                                                        
   \<200                 1,169   46%(41--51)   5.51(4.47,6.78)   \< .0001   5.10(4.11,6.33)   \< .0001
   200--349              868     70%(63--75)   1.06(0.81,1.38)   0.6872     1.13(0.86,1.47)   0.3865
   350--499              667     80%(74--84)   0.77(1.81,2.92)   0.0757     0.80(0.60,1.06)   0.1223
   ≥500                  665     80%(75--84)   1.00              \-         1.00              \-

CI: Confidence Interval

\*Individuals were classified by initial CD4+ T-cell counts within 6 months of HIV diagnosis, including individuals who died from AIDS within 6 months of HIV diagnosis. Individuals without CD4+ T-cell counts or CD4+ T-cell counts measured greater than 6 months of HIV diagnosis were designated as the \"missing group\" (data not shown).

The survival by epidemiologic characteristics and immune status at HIV diagnosis
--------------------------------------------------------------------------------

The median survival of HIV-infected individuals following diagnosis was 16.7 (data not shown). Figure [1](#F1){ref-type="fig"} showed survival of HIV-infected individuals by epidemiological characteristics. Women had longer survival than men (p = 0.0442), a younger age at initial HIV diagnosis was associated with a significantly longer survival (p \< 0.0001). HIV-infected individuals identified in blood centers demonstrated the longest survival, followed by individuals from public institutions and hospitals (p \< 0.0001). Individuals diagnosed between 2003 and 2007 demonstrated longer survival (p = 0.0039).

![**Survival after HIV diagnosis stratified by epidemiologic characteristics**. A, Gender; B, Age; C, Screening site; and D, Year of diagnosis.](1471-2334-9-128-1){#F1}

Survivals stratified by CD4+ T-cell counts at HIV diagnosis were shown in Figure [2](#F2){ref-type="fig"}. HIV-infected individuals with CD4+ T-cell counts \<200 cells/mm^3^at HIV diagnosis demonstrated 46% survival at 10 years after diagnosis. However, individuals with CD4+ T-cell counts ≥200 cells/mm^3^demonstrated approximately 77% survival in the same time period (data not shown).

![**A, Level of CD4+ T-cell counts at HIV diagnosis over calendar year, and B, Survival stratified by CD4+ T-cell counts at HIV diagnosis (The survival curve of \"missing group\" was not shown)**.](1471-2334-9-128-2){#F2}

Table [2](#T2){ref-type="table"} showed the proportion of 10 years survival after HIV diagnosis. It also analyzed estimation Cox\'s hazard ratio by epidemiological variables. The adjusted relative hazard ratio (AHR) by gender was approximately 1.4-fold higher in men than in women (p = 0.0082). Individuals aged 29 years or younger had lower AHRs than individuals aged 30--39 years (AHR, 1.46; p = 0.0003), and individuals aged 40--49 years (AHR, 2.10; p \< 0.0001), individuals aged 50--59 years (AHR, 3.08; p \< 0.0001). Survival stratified by screening site was higher in PHCs than in hospitals (AHR, 1.50; p \< 0.0001), and longer survival was observed in individuals diagnosed in blood centers (AHR, 0.62; p = 0.0067). Survival were shorter in the individuals diagnosed prior to 1990 than in individuals diagnosed between 2003 and 2007 (AHR, 5.03; p \< 0.0001). Survival was shorter in individuals with CD4+ T-cell counts \<200 cells/mm^3^than in individuals with CD4+ T-cell counts ≥500 cells/mm^3^(AHR, 5.10; p \< 0.0001). Individuals with CD4+ T-cell counts ≥200 cells/mm^3^displayed similar survival.

Table [3](#T3){ref-type="table"} showed the comparison of survivals by epidemiological variables in year of diagnosis. Survival in individuals aged 30--39 years and in individuals with 200--349 cells/mm^3^of CD4+ T-cell counts have increased after HAART.

###### 

Survival following HIV diagnosis and the estimated hazard ratio of variables by year of diagnosis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                      1985--1990   1991--1996       1997--2002   2003--2007                                                                         
  ---------------------- ------------ ------------ ---------------- ------------ ------------ --------------- ---------- ------- --------------- ---------- ------- ---
  Gender                                                                                                                                                            

                                                                                                                                                                    

   Men                   Unadjusted   105\         2.2(1.7--2.9)    \< .0001     440\         1.5(1.2--1.9)   \< .0001   1230\   1.3(1.1--1.6)   0.001      3082\   1
                                      (85)                                       (89)                                    (89)                               (93)    

                         Adjusted                  4.3(3.2--5.9)    \< .0001                  3.0(2.4--3.7)   \< .0001           1.3(1.1--1.5)   0.0022             1

                                                                                                                                                                    

   Women                 Unadjusted   19\          2.4(1.0--6.0)    0.0513       57\          2.3(1.1--4.6)   0.0209     158\    1.5(0.8--2.8)   0.2444     232\    1
                                      (15)                                       (11)                                    (11)                               (7)     

                         Adjusted                  4.3(1.6--11.4)   0.0037                    4.2(2.0--9.0)   0.0001             1.6(0.9--3.1)   0.1402             1

                                                                                                                                                                    

  Age                                                                                                                                                               

                                                                                                                                                                    

   ≤ 29                  Unadjusted   60\          3.7(2.0--7.0)    \< .0001     198\         2.0(1.1--3.6)   0.0188     339\    1.4(0.8--2.5)   0.2553     766\    1
                                      (48)                                       (40)                                    (24)                               (23)    

                         Adjusted                  4.8(2.5--9.3)    \< .0001                  2.9(1.6--5.3)   0.0007             1.5(0.9--2.8)   0.1514             1

                                                                                                                                                                    

   30--39                Unadjusted   40\          3.5(2.2--5.7)    \< .0001     184\         2.6(1.8--3.7)   \< .0001   472\    1.7(1.2--2.3)   0.0016     1062\   1
                                      (32)                                       (37)                                    (34)                               (32)    

                         Adjusted                  6.6(3.9--11.1)   \< .0001                  4.1(2.8--6.0)   \< .0001           1.7(1.2--2.3)   0.0016             1

                                                                                                                                                                    

   40--49                Unadjusted   18\          2.3(1.3--4.1)    0.0065       76\          2.5(1.7--3.6)   \< .0001   323\    1.4(1.1--1.9)   0.0181     803\    1
                                      (15)                                       (15)                                    (23)                               (24)    

                         Adjusted                  2.4(1.3--4.4)    0.0072                    3.2(2.2--4.7)   \< .0001           1.4(1.0--1.9)   0.0293             1

                                                                                                                                                                    

   ≥ 50                  Unadjusted   6\           3.7(1.6--8.3)    0.0019       39\          1.5(1.0--2.4)   0.0755     254\    1.2(0.9--1.5)   0.2709     683\    1
                                      (5)                                        (8)                                     (18)                               (21)    

                         Adjusted                  5.1(2.2--12.0)   0.0002                    2.7(1.7--4.4)   \< .0001           1.1(0.8--1.5)   0.4569             1

                                                                                                                                                                    

  Screening site                                                                                                                                                    

                                                                                                                                                                    

   Public institution    Unadjusted   86\          3.5(2.2--5.8)    \< .0001     295\         2.4(1.6--3.8)   0.0001     388\    1.8(1.1--2.8)   0.0148     621\    1
                                      (69)                                       (59)                                    (28)                               (19)    

                         Adjusted                  4.5(2.7--7.4)    \< .0001                  3.1(2.0--4.9)   \< .0001           1.7(1.1--2.7)   0.0248             1

                                                                                                                                                                    

   Hospital              Unadjusted   17\          3.7(2.1--6.5)    \< .0001     121\         2.8(2.1--3.7)   \< .0001   857\    1.6(1.3--1.8)   \< .0001   2451\   1
                                      (14)                                       (24)                                    (62)                               (74)    

                         Adjusted                  4.0(2.3--7.1)    \< .0001                  3.5(2.7--4.7)   \< .0001           1.4(1.2--1.7)   0.0003             1

                                                                                                                                                                    

   Blood center          Unadjusted   21\          2.5(0.5--11.3)   0.2406       81\          1.5(0.3--6.1)   0.6111     143\    0.7(0.2--3.1)   0.6275     242\    1
                                      (17)                                       (16)                                    (10)                               (7)     

                         Adjusted                  4.9(1.0--25.1)   0.0546                    2.2(0.5--9.8)   0.3165             0.9(0.2--4.1)   0.8896             1

                                                                                                                                                                    

  CD4+ T-cell counts\*                                                                                                                                              

                                                                                                                                                                    

   \<200                 Unadjusted   10\          1.6(1.0--2.5)    0.0707       63\          1.9(1.5--2.5)   \< .0001   313\    1.2(1.0--1.5)   0.0221     783\    1
                                      (20)                                       (18)                                    (35)                               (37)    

                         Adjusted                  2.7(1.6--4.4)    0.0001                    2.8(2.1--3.7)   \< .0001           1.3(1.1--1.6)   0.0063             1

                                                                                                                                                                    

   200--349              Unadjusted   3\           5.0(2.2--11.7)   0.0002       71\          2.7(1.4--5.4)   0.0035     212\    1.1(0.6--2.1)   0.7649     582\    1
                                      (6)                                        (21)                                    (24)                               (28)    

                         Adjusted                  6.3(2.6--15.0)   \< .0001                  2.7(1.4--5.5)   0.005              1.0(0.5--2.0)   0.9749             1

                                                                                                                                                                    

   350--499              Unadjusted   13\          1.9(0.7--5.3)    0.2351       90\          1.0(0.4--2.7)   0.9422     172\    0.8(0.3--2.1)   0.7298     392\    1
                                      (25)                                       (26)                                    (19)                               (19)    

                         Adjusted                  2.6(0.9--7.7)    0.081                     1.1(0.4--3.0)   0.8152             0.9(0.3--2.2)   0.7546             1

                                                                                                                                                                    

   ≥ 500                 Unadjusted   25\          3.4(1.4--8.4)    0.0076       120\         2.1(0.9--4.9)   0.1056     192\    1.3(0.5--3.1)   0.6153     328\    1
                                      (49)                                       (35)                                    (22)                               (16)    

                         Adjusted                  3.5(1.3--9.0)    0.0117                    2.2(0.9--5.4)   0.0966             1.3(0.5--3.1)   0.6118             1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: Confidence Interval, HR: Hazard Ratio

\*Individuals were classified by initial CD4+ T-cell counts within 6 months of HIV diagnosis, including individuals who died from AIDS within 6 months of HIV diagnosis. Individuals without CD4+ T-cell counts or CD4+ T-cell counts measured greater than 6 months of HIV diagnosis were designated as the \"missing group\" (data not shown).

Discussion and conclusion
=========================

The survival following HIV diagnosis in Korea was 16.7 years in this study. Survival in individuals diagnosed between 2003 and 2007 was 5.0- and 3.5-fold higher in individuals diagnosed prior to 1990 and between 1991 and 1996, respectively. This suggested the presence of positive therapeutic effects in survival of HIV-infected individuals based on introduction of government supported-antiretroviral therapy. Several hospitals were designated as AIDS care centers in 1989 during the early periods of therapeutic support in Korea \[[@B13]\]. However, this system was abolished due to the prohibition of discrimination against HIV-infected individuals in 1999. The number of HIV treatment hospitals increased to 60 hospitals in 2007 \[[@B14]\]. Survival was increased during AZT treatment periods (1991--1996) compared to non-treatment periods (1985--1990), in spite of no effect of AZT on survival in other studies \[[@B15]\]. This may be the result of increased immunity due to dietary health support products such as Korean red ginseng, increased support for HIV-infected individuals, and rapid contact with hospitals rather than due to therapeutic effect of AZT \[[@B16],[@B17]\]. During HAART era, the survival was longer in 2003--2007 compared to survival in 1997--2002. This could be associated with appropriate HIV RNA quantitation and drug resistance testing for efficient therapy. In addition, the increased 17 available drugs compared to 15 available drugs before 2003 may have positive effect on survival in 2003--2007 \[[@B18]\]. The most efficient therapeutic effect in the group with CD4+ T-cell counts of 200--349 cells/mm^3^was due to the initiation and continued HAART in newly diagnosed individuals with CD4+ T-cell counts \<350 cells/mm^3^according to CDC guidelines. However, HAART in newly-diagnosed individuals with CD4+ T-cell counts \<200 cells/mm^3^did not appear efficacious.

The immune status of newly diagnosed individuals revealed low CD4+ T-cell counts, suggesting that HIV diagnosis was delayed after primary infection \[[@B8]\]. Individuals with CD4+ T-cell counts ≥200 cells/mm^3^had longer survival than individuals with CD4+ T-cell counts \<200 cells/mm^3^. Survival of individuals with CD4+ T-cell counts \<200 cells/mm^3^was increased to 13 years compared to previous results from Korea (3.6 years) and USA (2.7 years) prior to HAART \[[@B8],[@B19]\].

The proportion of individuals who died within 6 months after HIV diagnosis was higher in Korea (45%) than in France (14%) or the United Kingdom (10--20%) \[[@B20],[@B21]\]. Approximately 70% of individuals who died within 6 months of diagnosis were diagnosed within 2 months prior to death (data not shown). Mortality was related to age \[[@B22]\] and decreased CD4+ T-cell counts, suggesting that older HIV-infected individuals were generally diagnosed at the late stages of disease. This suggested that early diagnosis is required to prevent HIV transmission and allow for appropriate HIV treatment in Korea.

AIDS mortality due to HIV-related causes has been reduced by HAART. However, non-HIV-related mortality has increased \[[@B23]\]. AIDS-associated mortality in Korea encompassed 70% of all deaths in HIV-infected individuals, and heart disease, liver disease, cerebral disease, and respiratory and pulmonary diseases were secondary causes of death. AIDS-related mortality in HIV-infected individuals has slowly decreased, although AIDS is still the primary cause of death in Korea \[[@B20]\]. Non-HIV-related deaths among HIV-infected individuals included drug-associated deaths in New York (1999 to 2004), cancer in Australia and the United States (2004), hepatic disease in Europe, and hepatic disease associated with hemophilia \[[@B24]-[@B28]\]. However, AIDS was still the primary cause for mortality due to late diagnosis after primary infection.

There are several limitations in this study. Survivals were estimated indirectly based on changes in drug introduction and development of therapy. Drug therapy for HIV infections follows CDC guidelines in Korea \[[@B29]\], so grouping based on drug therapy introduction times is reasonable. However, further study is required to characterize survival based on Korean therapeutic effects, and main survival factors require the investigation of therapy acceptance or rejection, the date of antiretroviral therapy initiation, antiretroviral dosages, treatment protocols, and compliance. The study also required the investigation of survival based on smoking and alcohol consumption as primary epidemiological factors of survival. Second, survival stratified by cause of death was not analyzed in this study due to numerous AIDS-associated syndromes and subjective decisions by physicians. Additionally, cardiovascular disease, diabetes, and hepatic disease can also cause death in AIDS patients, as can myocardial infarction and metabolic complications as therapeutic side effects \[[@B30]\]. Therefore, the standardization of causes of death in HIV-infected individuals should analyze survival based on cause of death. Lastly, individuals without CD4+ T-cell counts or with CD4+ T-cell counts collected greater than 6 months after HIV diagnosis were designated the \"missing group\" during analysis. However, there were no differences between individuals with initial CD4+ T-cell counts measured within 6 months after HIV diagnosis (including individuals who died during this time period) and the \"missing group\" in survival stratified by immune status at diagnosis (HR: 0.94; \[95% confidence interval, 0.80--1.11\]; p = 0.4693).

Survival after HIV diagnosis in Korean populations has been recently increasing. A delayed diagnosis results in missed therapeutic opportunities, while an early diagnosis may increase survival and the quality of life in HIV-infected individuals supported by governmental programs. The best way to improve rates of early diagnosis in asymptomatic individuals is to test as many individuals as possible. Korean government made a stipulation for anonymous testing system in March 2008 to minimize the fear for identity exposure by HIV testing \[[@B31]\]. Anonymous testing services need to be improved in PHC and voluntary counseling and testing centers.

This study is the first to investigate survival of HIV-infected individuals in Korea. Future studies should evaluate survival characteristics based on disease progression to AIDS, administration of antiretroviral drugs, therapeutic protocols, and antiretroviral drug resistance.
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